| Biomarker ID | 483 |
| PMID | 20632177 |
| Year | 2010 |
| Biomarker | MMP-2 |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated and Hypermethylated (PCa: 684.65 ± 129.36; Normal: 609.63 ± 172.58) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Bladder cancer,Plasma membrane estrogen receptor signaling,Angiopoietin receptor Tie2-mediated signaling,LPA receptor mediated events,Alpha-M beta-2 integrin signaling |
| Experiment | Prostate Cancer Vs No Tumor |
| Type of Biomarker | Diagnostic |
| Cohort | 114 men were chosen for the study out of which 79 had no tumor and 34 had Prostate Cancer. |
| Senstivity | 24.1% [11–43.4] |
| Specificity | 78.6% [95% CI: 66.8–87.1] |
| AUC | 0.706 ± 0.08 |
| Accuracy | NA |
| Level Of Significance | p=0.038 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MMP2 |